Silver nanoparticles enhance the efficacy of aminoglycosides against antibiotic-resistant bacteria
Silver nanoparticles combined with aminoglycosides effectively target antibiotic-resistant bacteria, enhancing antibiotic efficacy and offering a potential solution to the growing resistance crisis by reducing bacterial resistance mechanisms.
Patent Information
- Application Number
- PCT/US2024/022160
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-29
- Filing Date
- 2024-03-29
- Publication Date
- 2024-11-07
AI Technical Summary
The increasing prevalence of antibiotic-resistant bacteria poses a significant threat to public health, with current antibiotics becoming ineffective, and there is a lack of new antibiotic development, necessitating alternative antimicrobial strategies.
Silver nanoparticles (AgNPs) are used in combination with aminoglycoside antibiotics to enhance their efficacy against antibiotic-resistant bacteria, leveraging their antimicrobial properties to target bacterial membranes and ribosomes, while being non-toxic to eukaryotic cells.
AgNPs demonstrate a bactericidal mode of action, reducing the minimum inhibitory concentration of aminoglycosides by up to 22-fold, showing promise as an adjuvant therapy to combat resistant bacteria without inducing cytotoxicity in mammalian cells.
Smart Images

Figure US2024022160_07112024_PF_FP_ABST
Abstract
Description
Attorney Docket 10457-551PC0 Silver Nanoparticles Enhance the Efficacy of Aminoglycosides Against Antibiotic-Resistant Bacteria BACKGROUND
[0001] The misuse of antibiotics across One Health sectors fuels an irreversible increase in resistance and renders clinically important antibiotics ineffective. Over 2.8 million antibiotic- resistant infections occur annually in the United States, leading to more than 35,000 deaths (CDC, 2019). A recent report estimates that globally, 1.27 million deaths were directly attributed to antimicrobial resistance (AMR) in 2019 (Murray et al., 2022). In addition to the immense cost to human life, AMR also leaves a global economic burden. The total annual economic losses in the United States have been as high as $20 billion in health care and $35 billion in productivity (CDC, 2013).
[0002] According to the 2019 CDC AMR report, some of the urgent threats to human health include carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacterales; while some of the serious threats include extended-spectrum β-lactamase- producing Enterobacteriaceae, multidrug-resistant (MDR) Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA) (CDC, 2019). All the pathogens listed can cause skin and soft tissue infections and are resistant to many commonly used antimicrobials. For example, Escherichia coli can cause necrotizing soft tissue infections (Bayard et al., 2021), P. aeruginosa is associated with burn wounds (Wu et al., 2011), both methicillin-resistant and sensitive strains of S. aureus are associated with hospital and community-acquired skin infections (Moffarah et al., 2016), and A. baumannii can cause skin and soft tissue infections, commonly seen in combat soldiers deployed to the Middle East (Sebeny et al., 2008). E. coli, S. aureus, K. pneumoniae, Streptococcus pneumoniae, P. aeruginosa, and A. baumannii are among the most prevalent AMR pathogens, collectively contributing to over 80% of all AMR-related deaths (Murray et al., 2022). Most of these bacteria are commonly referred to as the ESKAPE pathogens (Boucher et al., 2009).
[0003] The availability of effective therapies is further limited by the lack of development of new antibiotics. Novel non-traditional antimicrobial approaches are currently being explored as potential therapeutics. Some of the most promising strategies include bacteriophage therapyAttorney Docket 10457-551PC0 (Kakasis and Panitsa, 2019), drug repurposing (Miró-Canturri et al., 2019), and silver nanoparticles (AgNPs) (Rai et al., 2009; Bruna et al., 2021).
[0004] For centuries, silver (Ag) has been known to have antimicrobial properties. It has been used for many purposes, including patented medical-grade products containing Ag as an antimicrobial agent (Sim et al., 2018). The expansion of more therapeutic options, like antibiotics in the 1940s, led to a decrease in the utilization of Ag for antimicrobial purposes. One of the first studies that led to a resurgence of interest in Ag used 0.5% Ag nitrate to treat burn wounds (Moyer et al., 1965). The current dearth of effective antibiotics has forced physicians to reach for archaic antibiotics with potentially life-threatening adverse effects (Falagas and Kasiakou, 2005). Therefore, it is not surprising that other therapeutics, including Ag, are re-emerging as antimicrobial candidates (Franci et al., 2015). DESCRIPTION OF DRAWINGS
[0005] Figure 1 shows the size distribution of AgNPs. (A) A graph showing particle size distribution for Formula 1 and 2 AgNPs. (B) Measurement parameters were obtained for Formula 1 and 2 AgNP samples. (C) Select electron micrographs of silver nanoparticles under high-angle annular dark-field STEM mode. Scale bar = 5 nm.
[0006] Figure 2 shows that AgNPs broadly inhibit the growth of bacteria. Growth of E. coli DH5α, P. aeruginosa PAO1, A. baumannii 17978, S. aureus 12600 and S. aureus MRSA 131 after incubation with 0–6.2 μg / mL AgNP Formula 1.1 was assessed by measuring OD600for 20 h at 37°C. Each growth curve is an average of three independent experiments with three internal replicates per run. Error bars represent SEM.
[0007] Figure 3 shows that AgNPs are bactericidal against E. coli. The minimum bactericidal concentration (MBC) of Formula 1.1 AgNPs for E. coli DH5α was 6.2 μg / mL, while the MIC was 3.1 μg / mL. The ratio between the two values is 2, indicating a bactericidal mode of inhibition. Bacterial growth was assessed by measuring OD600 for 20 h, followed by plating for CFUs. The MIC and MBC points are marked on the graph. Data represent three independent experiments with three internal replicates per run.Attorney Docket 10457-551PC0
[0008] Figure 4 shows AgNP cytotoxicity assessed using different cell types. (Figure 4A) The assessment of AgNP cytotoxicity to HeLa, pre-treated for 24 h, mESC, pre-treated for 18 h, THP- 1, pre-treated for 24 h, and RAW 264.7 cells, pre-treated for 4 h, reveals cell type-specificity. (Figure 4B) The effect of AgNPs on bacterial uptake by phagocytic macrophages at non-cytotoxic concentrations. Error bars represent SEM. Percent alive values were normalized to the control. Statistical significance was calculated using a one-way analysis of variance (ANOVA) followed by multiple comparison Dunnett’s post-hoc test (***p < 0.0005, ****p < 0.0001). Error bars represent SEM. Data represent three independent experiments with three internal replicates per run.
[0009] Figure 5 show the effect of AgNPs on translation fidelity. Bar graphs representing relative rates of readthrough three stop codons: UGA (top), UAG (left), and UAA (right). Dose–response concentrations of aminoglycosides paromomycin and gentamicin were used as positive controls. Each bar is an average of a minimum of three biological replicates. Error bars represent standard deviation (StDev). Statistical significance was calculated using the Student t-test (*p < 0.05, **p < 0.01).
[0010] Figure 6 shows the effect of AgNPs on C. elegans motility and lifespan. (Figure 6A) C. elegans motility was assessed in the presence of 0.2 and 1.0 μg / mL of AgNPs and a non-treated control by measuring the number of body bends (thrashing) per 30 s in a total of 40 worms per each group. (Figure 6B) C. elegans lifespan was assessed in non-treated control worms and in the presence of 0.2 and 1.0 μg / mL of AgNPs using a total of 100 worms per group. Error bars represent SEM. Statistical significance was calculated using a one-way analysis of variance (ANOVA) followed by multiple comparison Dunnett’s post-hoc test (****p < 0.0001) for motility and the Kaplan–Meier survival analysis for lifespan. The difference in lifespan between the control and 0.2 and 1.0 μg / mL AgNPs was non-significant.
[0011] Figure 7 shows the TEM images of AgNP-treated E. coli cells. E. coli cells were incubated for 6 h with H2O control, 0.2 μg / mL, 3.1 μg / mL, and 7.2 μg / mL. The samples were immediately fixed to Formvar / carbon grids. Each grid was stained for 20 s with 0.5% uranyl acetate and imaged with Tecnai G2 Spirit TWIN 120 kV TEM. While arrows point to the observed dark staining of the extracellular matrix. Scale bars = 1 μm.Attorney Docket 10457-551PC0
[0012] Figure 8 shows the antimicrobial efficacy of AgNPs in combination with antibiotics. (Figure 8A) A graph representing the enhancement of E. coli DH5α inhibition (Fold Change) upon treatment with 0.2 μg / mL AgNPs and various combinations of antibiotics that target the bacterial membrane, DHFR, and the ribosome. (Figure 8B) E. coli DH5α growth curves assessing the antimicrobial effect of AgNPs alone or in combination with amikacin. Data represent the average of three independent runs with three replicates each. (Figure 8C) Bar graphs representing relative rates of readthrough the UGA stop codon in the absence (− AgNPs) and presence (+ AgNPs) of nanoparticles in combination with aminoglycoside antibiotics, amikacin (10.4 μg / mL) and gentamicin (1.3–10.4 μg / mL). Each bar is an average of a minimum of three biological replicates. Error bars represent StDev.
[0013] Figure 9 shows the checkerboard analysis of AgNP and amikacin combination against MDR E. coli. A dose–response combination of AgNPs with amikacin was tested against (Figure 9A) E. coli 0494, amikacin-sensitive strain and (Figure 9B) E. coli 0346, amikacin-resistant strain. The checkerboard represents an average of three independent experiments. The FICI for the amikacin-sensitive strain indicates a partial synergy. See Methods 3.1 for details. FICI = FICAgNP + FICAmikacin; FICAgNP = MICAgNP combination / MICAgNP alone; FICAmikacin = MICAmikacincombination / MICAmikacinalone. ΣFICI = (0.755 / 1.55) + (0.25 / 8.0) = 0.52.
[0014] Figure 10 shows a TEM image and an Image J image of AgNPs.
[0015] Figure 11 shows graphs of E. coli OP50 treated with AgNPs at various concentrations. FIG. 11A shows treatment with AgNPs. FIG. 11B shows treatment with FUDR.
[0016] Figure 12 shows graphs of effects of various controls on E. coli. FIG. 12A shows effects of DMSO, FIG. 12B shows effects of water and FIG. 12C shows effects of ethanol. DETAILED DESCRIPTION
[0017] As the threat of antimicrobial-resistant bacteria compromises the safety and efficacy of modern healthcare practices, the search for effective treatments is more urgent than ever.Attorney Docket 10457-551PC0
[0018] The recent advancements in nanotechnology leading to the development and characterization of AgNPs have significantly broadened the potential application of Ag. Numerous studies demonstrated the antimicrobial property of AgNPs against a variety of antibiotic-resistant bacteria, including MRSA, erythromycin-resistant Streptococcus pyogenes, ampicillin-resistant E. coli, MDR P. aeruginosa, Listeria monocytogenes, Klebsiella pneumoniae, and K. aerogenes (Lara et al., 2010; Brown et al., 2012; Bose and Chatterjee, 2016; Mohamed et al., 2020; Campo- Beleño et al., 2022).
[0019] Although the exact mechanism of their antimicrobial property is not known, various reports suggest that they target the bacterial cell membrane (Jung et al., 2008; Bondarenko et al., 2018) and the ribosome and protein synthesis (Yamanaka et al., 2005). There is also evidence that AgNPs increase the generation of reactive oxygen species, leading to oxidative stress and, ultimately, DNA and protein damage (Park et al., 2009). Furthermore, AgNPs were shown to be involved in the disruption of cellular signal transduction pathways (Shrivastava et al., 2007).
[0020] The size and shape of AgNPs affect their antibacterial property, with smaller spherical and triangular particles having the highest efficacy (Pal et al., 2007; Raza et al., 2016; Dong et al., 2019). It was shown that a size decrease from ~11 to ~3 nm led to an enhancement of AgNP antibacterial activity, and particles between 1 and 10 nm had optimal antibacterial properties (Morones et al., 2005; Bin Ahmad et al., 2012). In one study, it was shown that a membrane of chitosan, gelatin, polyvinyl pyrrolidone and AgNPs incubated with bacteria led to reduced expression of mecA and erm resistance genes in S. aureus and Bacillus subtilis, and β-lactamase and erm in E. coli and Salmonella typhi. Over-expression of these genes induces tolerance to antibiotics; hence, this membrane was developed as a potential wound dressing supplemented with AgNPs to help prevent MDR infections in burn wounds and other AMR skin infections (El-Aassar et al., 2021).
[0021] AgNPs that showed antibacterial activity against E. coli and S. aureus in vitro also promoted faster wound healing in a mouse model (Chinnasamy et al., 2021). These results have been corroborated by other studies that demonstrated the wound-healing properties of AgNPs and their antimicrobial activity against methicillin-resistant Staphylococcus pseudintermedius wound infection (Thammawithan et al., 2021; Zhou et al., 2021). AgNPs were also shown to enhance the effectiveness of several antibiotics, including amoxicillin, penicillin G, erythromycin,Attorney Docket 10457-551PC0 vancomycin, clindamycin, imipenem, and cefixime (Shahverdi et al., 2007; Naqvi et al., 2013; Ali et al., 2020); however, the underlying mechanisms remain unknown.
[0022] In this disclosure, the efficacy and toxicity of AgNPs was calculated as a potential antimicrobial against a broad spectrum of bacteria, including those with novel mechanisms of resistance. Additionally, the direct bactericidal effects and synergy of AgNPs with aminoglycoside antibiotics, as seen with a 22-fold reduction in minimum inhibitory concentration (MIC) of amikacin, suggest a promising utility of AgNPs as antibiotic adjuvants. Furthermore, the lack of cytotoxicity to cells, no effect on C. elegans lifespan, and no proteotoxic property of AgNPs support their use for broad antimicrobial applications.
[0023] Some embodiments relate to administering AgNPs as described herein in combination with antibiotics to treat bacterial infections in a subject. According to one embodiment disclosed herein, provided is a method of treating bacterial wound infection in a mammalian subject in need thereof that involves co-administering effective amounts of AgNPs and antibiotics. Examples of antibiotics include aminoglycosides such as streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate.
[0024] Other embodiments relate to a method of treating respiratory diseases caused by bacterial infection in a mammalian subject in need thereof, comprising a step of co-administering effective amounts of AgNPs and antibiotics. Examples of respiratory diseases include pneumonia, cystic fibrosis, and multidrug-resistant tuberculosis. In a specific embodiment, the antibiotic implemented is an aminoglycoside, such as streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate.
[0025] These and other embodiments are described further herein. Definitions
[0026] The preferred materials and methods are described herein; any methods and materials similar or equivalent to those described herein can be used in the practice of or testing of the invention. Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the inventionAttorney Docket 10457-551PC0 pertains. In describing and claiming the present invention, the following terminology will be used. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and it is not intended to be limiting.
[0027] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless specifically stated otherwise.
[0028] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In a specific embodiment, the term “about” includes a stated numerical value as well as a value that is + / - 15% of the stated numerical value. For example, about 5.75 M includes 5.75 molar as well as 6.61 M and 4.89 M, and all 1 / 10 values in between. In many instances, the term “about” may include numbers that are rounded to the nearest significant figure.
[0029] As used herein, the terms “administer,” “administering” and “administration,” when used with respect to an agent, mean providing the agent to a subject using any of the various methods or delivery systems for administering agents or pharmaceutical compositions known to those skilled in the art. Typical routes of administration may include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intradermal, intracerebral, intrathecal, and intranasal. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intraperitoneal, intrapleural, intrasternal injection, directly into the lumen of the bladder, or infusion techniques. In a specific embodiment, the compositions are administered orally, topically, or parenterally. Pharmaceutical compositions can take the form of one or more dosage units, e.g., a tablet or a capsule.
[0030] The term “co-administer”, “co-administration” or “co-administering” as used herein refer to the administration of a substance before, concurrently, or after the administration of another substance such that the biological effects of either substance overlap.
[0031] As used herein, the term ”silver nanoparticles (AgNPs)” refers to nanoparticles of silver between 1 nm and 100 nm in size. It has been found that AgNPs of different sizes, shapes (spherical, triangle, cubic, disc, rod, tube, wire, etc.) and surface charges (positive, negative,Attorney Docket 10457-551PC0 neutral) may have differences in their kinetics of uptake, intracellular accumulation, secretion, and the resulting biological effect (Xu et al., 2020). In general, smaller particles (10 nm, 20 nm) can easily penetrate cells and more cytotoxic, while larger particles (100 nm) appeared mainly on the cell surface (Jeong et al., 2014; Wu et al., 2019). In addition, neutral or negatively charged charged AgNPs appear to adhere to cell membranes, while positively charged AgNPs are more efficient for cell membrane penetration and internalization (El Badawy et al., 2010). The synthesis methods of AgNPs can be divided into two types of approaches: top-down and bottom-up. The top-down approach refers to the formation of AgNPs from bulk materials, while the bottom-up approach refers to the formation of Ag NPs by growing silver complex clusters from molecular components. • The top-down approach, mainly the physical methods, uses mechanical energy (ball milling method), electrical energy (electrical arc-discharge method), electrical / light energy (laser ablation method), and electrical / thermal energy (physical vapor deposition) to reduce particle size. Physical synthesis is a method for producing AgNPs on a large scale, however AgNPs may aggregate and form large-sized particles which may affect subsequent applications. To prevent the re-aggregation of AgNPs and obtain stable colloids AgNPs, some stabilizers can be used. Using physical methods, AgNPs of high purity and uniform particle size distribution can be obtained, but this approach requires complex equipment and external energy are required. • The bottom-up approach includes chemical synthesis and biological synthesis, and it refers to the formation of AgNPs by constructing silver complex clusters from molecular components through nucleation and growth processes by reducing the silver precursor salt (Ju-Nam et al., 2008, Yadav et al., 2012). • Chemical synthesis is the most commonly used method to obtain AgNPs. This method involves the reduction of silver ions (Ag+) of silver salt to silver atoms through electron transfer under certain conditions. For chemical synthesis, reducing agents such as sodium borohydride (NaBH4) and sodium citrate (TSC) can be used. The process includes steps of nucleation, seeding and growth. As the silver monomer concentration in the solution rapidly rises above the critical level of supersaturation, precipitation and “burst-nucleation” occur (Vreeland et al., 2015; Naik et al., 2019). The precipitation of the monomer forms the nucleus, and the repetitive nucleation process promotes the continuous generation of new seeds. The increased addition of monomer induces the growth of nuclei and formsAttorney Docket 10457-551PC0 NPs with a larger size. Size and shape of AgNPs can be controlled by regulating the growth rate of nucleation. Besides reducing agents, capping agents and stabilizers are also added to obtain AgNPs with good dispersion stability and uniform size distribution. In addition, external energy can be used synergistically to synthesize AgNPs, such as microwave, light, heat, and sound (Elsupikhe et al., 2015; Pu et al., 2018; Joseph S. and Mathew B. 2015; Pompilio et al., 2018). Although chemical synthesis methods of AgNPs are widely used, the toxicity and pollution caused by chemicals must be highlighted and more attention should be given. • Compared with physical and chemical methods, the biological methods are economical and environmentally friendly. The biological methods use macromolecules in bacteria, fungi, and algae such as exopolysaccharide, cellulose, and enzymes, and organic components in plant extracts such as enzymes, alcohol, flavonoids, alkaloids, quinines, terpenoids, phenolic compounds to reduce silver salts (Pantidos 2014; Hamedi et al., 2017; Al Abboud 2018; Khan et al., 2016; Kuppusamy et al., 2016). Furthermore, some organic substances among these can also be used as stabilizers and capping agents (de Morais et al., 2015). Biological synthesis may be simple and reliable, but the additives on the surface of nanoparticles must be considered in the application.
[0032] As used herein, the term “Gram-positive bacteria” refers to a group of bacteria that turn purple in the Gram stain test due to the trapped stain (crystal violet precipitated with iodine, which is not washed with alcohol and acetone-based decolorizer) in a thick, cross-linked, mesh-like structure (the peptidoglycan layer) of the cell wall. Examples of Gram-positive bacteria are Staphylococcus aureus, Streptococcus pyogenes, Streptococcus tuberculosis, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium urealyticu, Enterococcus faecalis, Enterococcus faecium,and Listeria monocytogenes.
[0033] As used herein, the term “Gram-negative bacteria” refers to a group of bacteria which cannot retain the crystal violet stain after the decolorization step because they have a thin peptidoglycan layer. They are counterstained (safranin or fuchsine) and appear red or pink. External to the peptidoglycan layer is the outer membrane, which is unique to Gram-negative bacteria. The area between the external surface of the cytoplasmic membrane and the internal surface of the outer membrane is referred to as the periplasmic space. This space is actually aAttorney Docket 10457-551PC0 compartment containing components of transport system for iron, proteins, sugars and other metabolites, and a variety of hydrolytic enzymes, such as proteases, phosphatases, lipases, nucleases, and carbohydrate-degrading enzymes. In the case of pathogenic Gram-negative species, many of the virulence factors, such as collagenases, hyaluronidases, proteases and ß-lactamase, are in the periplasmic space. Examples of Gram-positive bacteria are Acinetobacter, Aeromonas, Bartonella, Bordetella, Brucella, Burkholderia, Campylobacter, Cardiobacterium, Eikenella, Escherichia, Francisella, Haemophilus influenzae, Helicobacter pylori, Kingella, Klebsiella, Legionella, Moraxella, Proteus mirabilis, Pseudomonas, Salmonella, Shigella, Stenotrophomonas, Streptobacillus, Vibrio, Yersinia species, etc.
[0034] As used herein, the term ‘mycobacteria” refers to a genus of over 190 species in the phylum Actinomycetota. Mycobacteria are weakly Gram-positive. They have a waxy cell wall composed of mycolic acid, which is distinguished with the acid-fast stain. Mycobacteria include M. avium complex, M. leprae, and M. tuberculosis complex.
[0035] As used herein, the term “antimicrobial agent” refers to medicines used to prevent and treat infections in humans, animals and plants. An antimicrobial agent is a natural or synthetic substance that kills microorganisms or inhibits their growth, such as bacteria, fungi, algae and parasites, and can be categorized into antibiotics, antivirals, antifungals and antiparasitics.
[0036] As used herein, the term “antibiotics” refers to medicines that treat bacterial infections in people and animals. They work by killing the bacteria or inhibits their growth. According to Merck Manual (https: / / www.merckmanuals.com / home / infections / antibiotics / overview-of-antibiotics), they can be classified into the classes of aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, glycopeptides and lipoglycopeptides (such as vancomycin), macrolides (such as erythromycin and azithromycin), monobactams (aztreonam), oxazolidinones (such as linezolid and tedizolid), penicillins, polypeptides, rifamycins, sulfonamides, streptogramins (such as quinupristin and dalfopristin) and tetracyclines
[0037] As used herein, the term “aminoglycosides” refers to a class of antibiotics, which irreversibly inhibits proteins synthesis by binding to 30S-subunit ribosomal proteins, eventually leading to cell death. They (1) interfere with the initiation complex of peptide formation, (2) cause misreading of mRNA, and (3) breakup polysomes into nonfunctional monosomes. Aminoglycosides include streptomycin, neomycin, kanamycin, amikacin, gentamicin, tobramycin,Attorney Docket 10457-551PC0 netilmicin, and plazomicin. Spectinomycin is chemically related to aminoglycosides and works in a similar way, however it is not available in the United States.
[0038] As used herein, the term “amikacin” refers to a semisynthetic derivative of kanamycin, which has similar pharmacokinetic properties and dosages, but is less toxic. Amikacin features an additional (S)-4-amino-2-hydroxybutyl (AHB) side chain into the 1-amino position of the deoxystreptamine moiety of kanamycin A, resulting in increased stability against most of the bacterial plasmid-mediated enzymes, which are responsible for resistance to aminoglycosides. Because of this, amikacin is active against many gentamicin- and tobramycin-resistant gram- negative bacteria, including many strains Pseudomonas aeruginosa. Strains of multi-drug resistant Mycobacterium tuberculosis are also susceptible to amikacin.
[0039] Like all aminoglycosides, amikacin is nephrotoxic and ototoxic, and serum concentration should be monitored. Amikacin is not absorbed orally and is given by either intramuscular or slow intravenous injection either once or twice daily or, in severe infections, three times daily. Amikacin should not be physically premixed with other drugs, but should be administered separately according to the recommended dose and route.
[0040] As used herein, the term “polymyxins” refers to antibiotics that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of Gram-negative bacteria to break up the cell membrane. Polymyxins B and E (also known as colistin; an antibiotic produced by the soil bacterium Bacillus polymyxa) are included in this class. Polymyxins are neurotoxic and nephrotoxic, so they are usually used only as a last resort if modern antibiotics are ineffective or are contraindicated, for example, infections caused by strains of multiple drug- resistant Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae. Polymyxins are less effective on Gram-positive bacteria, eukaryotic microbes and mammalian cells, and are sometimes combined with other agents (as with trimethoprim / polymyxin) to broaden the effective spectrum. Since Polymyxins are not absorbed from the gastrointestinal tract, they are administered through parenteral (often intravenously) route or inhalation, or applied externally as a cream or ointment to treat skin infections.
[0041] As used herein, the term “multidrug resistance” refers to antibacterial resistance which happens when bacteria develop the ability to defeat the drugs designed to kill them. That means bacteria are not killed and continue to grow. CDC typically uses this term to refer to an isolate thatAttorney Docket 10457-551PC0 is resistant to at least one antibiotic in three or more antibiotic classes. Multidrug resistance mechanisms fall into four main categories: (1) limiting uptake of a drug; (2) modifying a drug target; (3) inactivating a drug; (4) active drug efflux. There are two main ways that bacterial cells can acquire antibiotic resistance. One is through mutations that occur in the DNA of the cell during replication. The other way that bacteria acquire resistance is through horizontal gene transfer through plasmids or transposons coding for resistance to a specific agent. Examples of bacteria resistant to antibiotics are methicillin-resistant Staphylococcus aureus (MRSA), vancomycin- resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB) and carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria.
[0042] As used herein, the term “subject” which can be used interchangeably with “patient” refers to an animal, preferably a mammal, or a human individual, which is to be treated with one or more enumerated therapy as taught herein. A “subject in need” for the invention can be any animal, preferably a human, that has been diagnosed with a disease that can be ameliorated or treated by administration of one or more enumerated agents.
[0043] The terms “treat” “treating” or “treatment of” as used herein refers to providing any type of medical management to a subject. Treating includes, but is not limited to, administering one or more drugs or agents comprising active ingredients to a subject using any known method for purposes such as alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilization (i.e., not worsening) of a state of disease, disorder, or condition; prevention of spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. “Palliating” a disease, disorder, or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.
[0044] As used herein, the term “dosage” refers to the administering of a specific amount, number, and frequency of doses over a specified period of time, and the term “dose” refers to a specified amount of medication taken at one time. A “dosage regimen” refers to the number of doses of a drug or medication, or agent (including bacteria) that a patient is supposed to take (or to beAttorney Docket 10457-551PC0 administered) over a specified period of time, and the individual doses that comprise the regimen are usually scheduled.
[0045] As used herein, the term “dosage form” refers to the form of pharmaceutical drug products with which they are marketed for use. Dosage forms are typically a mixture of active drug ingredients and inactive components (excipients), in a particular configuration (such as a capsule shell, for example), and apportioned into a particular dose.
[0046] As used herein in the context of bacterial infection, the term “therapeutically effective amount” refers to an amount of a composition of the disclosure that when administered to a subject in need thereof, is sufficient to effect treatment or prophylaxis for bacterial infection. The amount that is therapeutically effective will depend upon the patient's size and gender, the stage and severity of the infection and the result sought. The full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations per day for successive days. For a given patient and condition, a therapeutically effective amount can be determined by methods known to those of skill in the art. For example, in reference to the treatment of a bacterial infection using the compositions of the present disclosure, a therapeutically effective amount refers to that amount of the composition which has the effect of (1) reducing the amount of bacteria in or on the subject, (2) reducing the duration of the infection, (3) reducing infectivity and / or, (4) reducing the severity (or, preferably, eliminating) one or more other symptoms associated with the infection such as, for example, fever, headache, fatigue, cough, sore throat, respiratory distress, muscle aches, conjunctivitis, runny and / or stuffy nose, for respiratory or other internal infections; and for topical infection, puss formation swelling, redness, and / or. Such an effective dose will generally depend on the factors described above. A prophylactically effective dose is one that reduces the likelihood of contracting a virus infection. Overview
[0047] Since the antibacterial efficacy of AgNPs varies with structure, size, and concentration. Five commercially available AgNPs were characterized to investigate their antimicrobial properties and potential utility for future applications. AgNP size distribution analysis revealed that particles range between 0.8 and 23 nm, with over 99% of particles being < 10 nm in diameter. The mean particle size was 2.53 ± 1.71 in Formula 1 and 3.06 ± 2.04 nm in Formula 2 (Figures 1AAttorney Docket 10457-551PC0 & B; Figure 10). In addition, the atomic structure of the AgNPs was determined for particles approximately 2 nm and larger, which showed a clear crystalline lattice structure. However, for particles smaller than 2 nm, the clear lattice structure was no longer detected (Figure 1C). The average Ag concentration of Formula 1 was determined to be 12.3 μg / mL and that of Formula 2 to be 26.8 μg / mL (Table 4). Additionally, measurement of the spacing of the atomic planes (d spacing) in the AgNPs revealed a commonly observed d spacing of 0.24 ± 0.01 nm, supporting that the particles are indeed elemental Ag.
[0048] Next, antimicrobial efficacy of AgNPs of Formula 1 and Formula 2 was tested in E. coli DH5α. The minimum inhibitory concentrations (MICs) were in the ~3 μg / mL range (Table 4), which is lower than other AgNP formulations (Lara et al., 2010) but higher than Ag ions alone (Jung et al., 2008; Li et al., 2017), indicating a consistent antimicrobial property of AgNPs of the formulations tested. A slight but significant difference in MIC values was observed that is positively correlated with the average size of the particles (Table 4), showing Formula 1 AgNPs having smaller size have lower MICs than Formula 2 AgNPs having larger size.
[0049] Next, three formulations of 0–6.2 μg / mL AgNPs (Formula 1.1, 2.1, and 2.2) were selected to test the antimicrobial activity against additional bacteria, including P. aeruginosa, A. baumannii, methicillin-resistant and susceptible S. aureus, K. pneumoniae, and Citrobacter freundii (Figure 2, Table 1). Bacterial growth was inhibited in a dose-dependent manner, and the low MICs (<6.2 μg / mL) were observed. Interestingly, all formulations tested were more effective against Gram-negative bacteria compared with Gram-positive S. aureus strains (Table 5). Among the three samples tested, Formula 1.1 was the most effective against all bacteria, especially against the Gram-negative; as such, this formulation was chosen for all future experiments.
[0050] While the mechanisms contributing to this difference are not known, it is thought that perhaps the dissociated Ag ions may more readily enter Gram-negative bacteria via outer membrane porins (Radzig et al., 2013). Other reports suggest that the thickness of the peptidoglycan layer is responsible for the difference in AgNP efficacy between Gram-positive and Gram-negative bacteria (Dakal et al., 2016). Regardless of the mechanisms responsible for the difference, the potent antimicrobial property against Gram-negative bacteria is promising as these organisms are notoriously known for their intrinsic resistance to many classes of antibiotics, leaving little to no treatment options available (Breijyeh et al., 2020).Attorney Docket 10457-551PC0
[0051] Further, to determine whether AgNPs are also effective against antibiotic-resistant bacteria, isolates carrying mobile colistin resistance (mcr) genes were tested (Table 2). While the antimicrobial property of AgNPs differed substantially against bacteria with various antibiotic resistance mechanisms (e.g., mcr-1, 3, 4, or bla) , the overall low MIC values that range from 3.1 to 5.5 μg / mL, except for some Salmonella spp., emphasize excellent antibacterial properties against broad antibiotic-resistant bacteria (Figure 2; Table 1). Among the bacteria tested, Salmonella spp. seem to be the least sensitive to AgNPs.
[0052] Next, the mode of inhibition was assessed with E. coli DH5α. The MIC was 3.125 μg / mL, and the minimum bactericidal concentration (MBC) was 6.2 μg / mL, resulting in a ratio of ~2, thus, revealing a bactericidal mode of killing (Figure 3).
[0053] Since Ag is also known for its cytotoxicity, which could limit its application as a broad oral antimicrobial, a tissue culture model and C. elegans model were employed to assess the cytotoxic effect of AgNPs. First, the effect of AgNPs on the viability of mouse macrophages RAW 264.7, human macrophages THP-1, human epithelial HeLa cells, and mouse embryonic stem cells mESCs was measured. While the epithelial cells were not affected by any of the tested concentrations, the viability of macrophages and mouse embryotic stem cells (mESCs) was affected at higher AgNP concentrations; however, the viability of all cultured cells was not affected at lower bactericidal concentrations (<1.6 μg / mL) of AgNPs, which already exhibit moderate antibacterial effects at sub-MIC levels (Figures 2 and 4A). This Ag sensitivity of phagocytic macrophages could be the result of enhanced particle uptake. Given the membrane-targeting property of Ag, the effect of AgNPs on macrophage-mediated bacterial uptake was also tested by pre-treating the macrophages for 4 or 24 h with non-toxic AgNP concentrations. It was found that bacterial uptake was not affected at the concentrations tested (Figure 4B). Macrophages are involved in wound healing and protection against bacterial invasion; as such, demonstrating the inert effect of AgNPs on phagocytosis could also warrant their possible use as an oral antimicrobial.
[0054] Since there are previous reports suggesting that Ag targets the bacterial ribosome (Yamanaka et al., 2005), it was necessary to investigate whether AgNPs may also affect the eukaryotic ribosome. To test whether AgNPs could induce misreading of mRNA in eukaryotic cells, translation errors were monitored using reporters based on a tandem renilla luciferase (Rluc)Attorney Docket 10457-551PC0 and firefly luciferase (Fluc) linked together with a region containing a stop codon (UGA, UAG, or UAA). The stop codon readthrough was monitored by Fluc activity, and the mistranslation rate was measured by calculating the ratio between Fluc and Rluc. While a significant increase in mistranslation was seen in the presence of paromomycin and gentamicin, two aminoglycoside antibiotics which induce misreading of mRNA by bacterial and eukaryotic ribosomes and ultimately lead to translation error which is likely the source of the proteotoxic stress (Prokhorova et al., 2017; Wohlgemuth et al., 2021; Davis, 1987; Vicens and Westhof, 2001; Kohanski et al., 2008; Krause et al., 2016), no changes of translation fidelity was detected in the presence of AgNPs of E. coli MIC concentration (3.1 μg / mL), indicating that the AgNPs are not proteotoxic to mammalian cells under the tested conditions (Figure 5).
[0055] Next, the effects of AgNPs on C. elegans motility and lifespan were measured using control non-treated worms or worms grown in the presence of 0.2 and 1.0 μg / mL of AgNPs. 0.2 μg / mL was chosen because this low concentration exhibited a minimal antimicrobial effect in the axenic medium and was non-toxic in tissue culture while 1.0 μg / mL had an intermediate antimicrobial effect (Figure 2). The worms on the AgNP-containing plates performed significantly fewer body bends compared with the control (Figure 6A). However, at the same concentrations, AgNPs did not seem to have adverse effects on lifespan (Figure 6B).
[0056] In addition, to determine whether AgNPs induce any visible morphological changes in bacterial cells, TEM was employed to image non-treated E. coli and cells treated with 0.2 μg / mL, 3.1 μg / mL, and 7.2 μg / mL for 6 h. Dark staining of the extracellular matrix seems to increase with AgNP concentration. These dark regions indicate high electron density, suggesting Ag may bind bacterial fimbriae (Figure 7). If this is the case, then one would expect detectable effects on bacterial attachment and biofilm formation. Given that fimbriae support bacterial virulent mechanisms (Spurbeck et al., 2011; Sarowska et al., 2019), targeting these structures could provide a novel approach to inhibit bacterial pathogenicity. In fact, the anti-biofilm properties of AgNPs were also observed in other studies (Mohanta et al., 2020; Siddique et al., 2020). Moreover, the cells incubated with the highest concentration of AgNPs seem to be darker, which could either indicate an increased Ag concentration or cell permeability which increases uranyl acetate staining. These results warrant further experimentation to confirm fimbriae binding and its possible physiological relevance.Attorney Docket 10457-551PC0
[0057] Ag is its ability to target antibiotic resistance mechanisms (Lara et al., 2010; Brown et al., 2012; Panáček et al., 2016; Mohamed et al., 2020; Malawong et al., 2021). Thus, the antimicrobial efficacy of AgNPs of 0.2 μg / mL, a concentration with a minimal effect (Figure 2), in combination with several antibiotics having various mechanisms of antibacterial action, was determined in E. coli DH5α.
[0058] The effect of the combination was assessed by measuring the MIC fold-change as the ratio between the MIC of the antibiotic alone and the MIC of the combination (Table 2; Figure 8A). There was little effect on the antibiotic MIC when AgNPs were tested in combination with antimicrobials that target the membrane except for colistin, which had a 6.9-fold decrease in the MIC. When the AgNPs were combined with 30S ribosome-targeting antibiotics of non-effective concentrations, specifically aminoglycosides, such as gentamicin (0.39μg / ml), tobramycin (0.20 μg / ml), and amikacin (0.39 μg / ml), the MICs decreased by 12, 19 and 22-fold, respectively, indicating a strong synergy between the two (Table 2; Figure 8B).
[0059] This result suggests that either Ag promotes aminoglycoside binding to the ribosome or increases intracellular aminoglycoside concentration by permeating the membrane. If the latter is the case, a robust MIC fold change in combination with other non-ribosomal-targeting antibiotics (i.e., trimethoprim) is expected, but such a synergistic effect was not observed. Trimethoprim, which targets dihydrofolate reductase (DHFR), had a 2-fold decrease in the MIC. Additionally, a combination of AgNPs with tetracycline, which also targets the 30S ribosomal subunit, did not result in synergy; therefore, the AgNP-mediated enhancement of antibiotics is not explained by permeability, but it is more likely that AgNPs and aminoglycosides share common targets and interact synergistically at specific sites of the bacterial ribosome.
[0060] It was thought that perhaps the synergistic effect between AgNPs and aminoglycosides might also affect the host cells by inducing translation errors; however, after testing the combination, no effect on the translation error was found in the host cells (Figure 8). Further testing of an AgNP dose–response combination with amikacin against MDR E. coli strains using the checkerboard assay also revealed an antimicrobial enhancement (Figure 9). Collectively, the antimicrobial efficacy of AgNPs and aminoglycosides offers a promising combination treatment strategy for antibiotic-resistant bacteria.Attorney Docket 10457-551PC0
[0061] Based on these results of the experiments described above and further explained in the Examples section, methods of treating bacterial wound infection as well as respiratory diseases caused by bacterial infection are provided.
[0062] In one embodiment, a method of treating bacterial wound infection is disclosed, comprising a step of co-administering effective amounts of silver nanoparticles (AgNPs) and antibiotics. The antibiotic is selected from the group of aminoglycosides comprising streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate. In particular, the antibiotic is gentamicin, tobramycin, amikacin or colistin, and the concentration of the antibiotic is not greater than its minimal inhibitory concentration (MIC).
[0063] The dosage form of gentamicin, tobramycin, amikacin or colistin may be, for example, an injection solution or a topical dosage form selected from solid form of powder or granules, semisolid form of cream, ointment, gel, or paste, liquid form of lotion or liniments, or liposome spray, and the antibiotic is administered through IV or IM route or topical or transdermal route.
[0064] In certain specific examples, AgNPs have a size range of between about 0.8 nm and about 23 nm, in particular between 2 nm and 10 nm, the mean particle size is 0.5 to 5.0 nm, and the concentration of AgNPs is less than about 0.7µg / ml, less than about 0.6 µg / ml, less than about 0.5 µg / ml, less than about 0.4 µg / ml, less than about 0.3 µg / ml, or less than about 0.2 μg / ml.
[0065] Topically dosage forms of AgNPs may include but are not limited to solid form of powder or granules, semisolid form of cream, ointment, gel, or paste, liquid form of lotion or liniments, or liposome spray. AgNPs can be applied to the wound using a transdermal patch coated with AgNPs or a wound dressing impregnated with AgNPs, wherein the wound dressing materials are selected from gauze, lint, plasters, bandages (natural or synthetic) and cotton wool.
[0066] In addition, certain embodiments relate to an antibiotic containing composition (e.g. topical formulation) that further includes AgNPs as an adjuvant.
[0067] The targeted bacteria include Gram-negative bacteria as well as multidrug resistant Gram- positive bacteria and Mycobacteria, in particular Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Citrobacter freundii, multidrug resistantAttorney Docket 10457-551PC0 Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium avium complex and M. tuberculosis.
[0068] In another embodiment, a method of treating respiratory diseases caused by bacterial infection is provided, comprising a step of co-administering effective amounts of silver nanoparticles (AgNPs) and antibiotics, and the respiratory disease includes but is not limited to pneumonia, cystic fibrosis, and multidrug-resistant tuberculosis. The antibiotic is selected from the group of aminoglycosides comprising streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate. In particular, the antibiotic pertains to gentamicin, tobramycin, amikacin or colistin, and the concentration of the antibiotic is not greater than its minimal inhibitory concentration (MIC) without co-administration of AgNPs.
[0069] In specific method embodiments, the dosage form of gentamicin, tobramycin, amikacin or colistin is an injection solution or a liposome spray for nebulization, and the antibiotic is administered through IV or IM route or nasal route.
[0070] In certain specific method embodiments, AgNPs are the particles of size range between 0.8 nm and 23 nm, in particular between 2 nm and 10 nm, the mean particle size is 0.5 to 5.0 nm, and the concentration of AgNPs is less than about 0.7µg / ml, less than about 0.6 µg / ml, less than about 0.5 µg / ml, less than about 0.4 µg / ml, less than about 0.3 µg / ml, or less than about 0.2 μg / ml. In a specific embodiment, the AgNPs are at a concentration of 0.2 μg / ml or less.
[0071] The dosage form of AgNPs is a dosage form of liposome spray for nebulization, wherein it is administered through the nasal route.
[0072] In addition, the liposome spray for nebulization of the antibiotic can comprise the liposome containing AgNPs as an adjuvant.
[0073] The targeted bacteria are Gram-negative bacteria as well as multidrug-resistant Gram- positive bacteria and Mycobacteria, in particular Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Citrobacter freundii, Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium avium complex and M. tuberculosis.Attorney Docket 10457-551PC0 EXAMPLES Example 1: Materials and methods
[0074] 1. Strains, chemicals, and culture materials
[0075] 1.1. Bacterial strains and culture: Bacterial strains used in this study include E. coli, P. aeruginosa, S. aureus, A. baumannii, Salmonella spp., K. pneumoniae, and Citrobacter freundii. More detailed information about each strain can be found in Table 3. Briefly, the clinical bacterial strains are MDR and carry novel resistance mechanism. The strains are made available through the Antibiotic Resistance Isolate Bank collection maintained by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). All bacteria were cultured at 37°C, shaking at 220 rpm. S. aureus and MRSA were cultured in Tryptic soy broth (TSB). All other strains were cultured in lysogeny broth (LB) Lennox.
[0076] 1.2. Tissue culture: Cell lines used in this study are found in Table 3. THP-1 cells were maintained in Roswell Park Memorial Institute 1640 medium (RPMI 1640) supplemented with 10% fetal bovine serum (FBS). Differentiation of THP-1 cells from monocytes to macrophages was performed by adding 40 ng / mL phorbol-12-myristate-13 acetate (PMA) to the cell medium and incubating for 72 h. RAW 264.7 macrophages and HeLa cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% FBS. The mouse embryonic stem cells (mESCs) were maintained in knockout DMEM supplemented with 1x L-glutamine, 1x non- essential amino acids, 0.1% 2-mercaptoethanol, leukemia inhibiting factor, 15% ESC grade FBS, and 1x ES grade penicillin / streptomycin. All cell experiments were performed at 37°C with 5% CO2 in a humidified environment.
[0077] 1.3. Caenorhabditis elegans culture: All experiments were performed at 25°C using the N2 wild-type strain (Table 3). Nematodes were maintained on a nematode growth medium (NGM) according to previously established protocols (Brenner, 1974).
[0078] 1.4. Chemicals: Chemicals and reagents are listed in Table 3. AgNPs were manufactured and supplied by Natural Immunogenics Corporation. Two types of AgNP products (Formula 1 and 2) were tested, and five batches from each formula were used. Aztreonam, cefoxitin, doripenem, and trimethoprim were dissolved in dimethyl sulfoxide (DMSO). Tetracycline was dissolved in ethanol, while all other antibiotics were dissolved in water.Attorney Docket 10457-551PC0
[0079] 2. Characterization of AgNPs
[0080] Ag concentrations were measured by atomic absorption spectroscopy (AAS). One milliliter of the sample was digested in 1 mL of 70% nitric acid using a microwave and then diluted to 10 mL using DI water. Triplicate measurements were performed for each sample.
[0081] Transmission electron microscopy (TEM) samples were prepared using Formvar-C coated 300 mesh Cu grids. A 1.0 μl drop was deposited onto each grid and allowed to dry in a desiccator. Bright-field transmission electron microscopy (BF-TEM) imaging was performed using a Phillips CM100 TEM operated at 100 kV to analyze the particle size distribution. Two grids were imaged, and a minimum of three images per grid were used to obtain average particle size data. The particle outlines were identified using ImageJ software. Images were visually inspected for artifacts to ensure the maximum inclusion of actual particles. The particle diameters were calculated from the outlined areas assuming a circular shape.
[0082] Additionally, atomic-resolution high-angle annular dark-field scanning transmission electron microscopy (HAADF-STEM) imaging was performed using an FEI Themis scanning TEM (S / TEM) with CS probe correction operated at 200 kV. This allowed direct visualization of the atomic structures of the AgNPs. Immediately prior to HAADF-STEM imaging, each grid was plasma cleaned for a few seconds using a Fischione Instruments Model 1,020 plasma cleaner. This was required for successful atomic-resolution HAADF-STEM imaging to occur; otherwise, the build-up of carbonaceous contamination during imaging prohibited this.
[0083] 3. Assessing minimum inhibitory concentrations and the antibacterial mode of inhibition of AgNPs
[0084] Serial dilutions of AgNPs were performed starting with 100 μl of undiluted stock added to the first row of a 96-well plate with 50 μl of LB per well in subsequent rows. An overnight culture was grown as described above; the optical density (OD600) was adjusted to 1.0, then diluted 1:500 in LB media, followed by aliquoting 50 μl to each well, resulting in a final dilution of 1:1000. All concentrations of AgNPs were ultimately diluted by half as a result of the addition of the bacteria to each well, leaving the highest concentration as half of the stock. The plate was incubated at 37°C in the Tecan Infinite 200 Pro plate reader for 20 h. Every 30 min, the plate was shaken orbitally for 5 s, and the OD600 readings were taken. The minimum inhibitory concentration (MIC)Attorney Docket 10457-551PC0 was defined as the lowest concentration that inhibited the growth of bacteria, as determined by a < 0.1 increase of OD600 over 20 h. The bactericidal or bacteriostatic activity of AgNPs was determined according to established protocols (Pankey and Sabath, 2004). To determine the minimum bactericidal concentration (MBC), after the 20 h reading, the culture was serially diluted and plated on LB agar. Colony-forming units (CFUs) were counted to determine the MBC. The ratio of the MBC to the MIC was found to be <4, indicating a bactericidal mode of inhibition. Experiments were performed with three independent runs of three replicates per run.
[0085] 3.1. Checkerboard assay Serial dilutions of amikacin were performed in water in a 96- well plate starting with 100 μl of 64 μg / mL of amikacin in row A and diluted into 50 μl of water until row G. Only water was added to row H. In a separate plate, 200 μl of 12.4 μg / mL AgNPs was added to column 12 and then diluted in 100 μl of water from columns 11–2. Only water was added to column 1. From the AgNP plate, 50 μl was transferred and added to the amikacin dilution plate. A culture of E. coli 0494 was grown overnight as described above; the OD600 was adjusted to 1.0, then diluted 1:500 using 2x MHB. A volume of 100 μl was added to each well bringing the final volume to 200 μl per well, the highest concentration of amikacin to 16 μg / mL, the highest concentration of AgNPs to 3.1 μg / mL, and the bacteria to a dilution of 1:1000. To test the E. coli 0346 isolate this procedure was repeated with the highest concentration of amikacin starting at 800 μg / mL, bringing the final concentration to 200 μg / mL. The plate was incubated at 37°C in the Tecan Infinite 200 Pro plate reader for 20 h. The endpoint OD600 reading was used to determine the MIC. Experiments were performed with three independent runs. The interaction between AgNPs and amikacin was assessed by calculating the fractional inhibitory concentration index (FICI), where the FICI = FICAgNP + FICAmikacin; FICAgNP = MICAgNP combination / MICAgNP alone; FICAmikacin = MICAmikacincombination / MICAmikacinalone. The FICI values indicate synergy (FICI ≤ 0.5), partial synergy (0.5<FICI ≤ 0.75), additive (0.75<FICI ≤ 1.0), indifferent (1.0 < FICI ≤ 4.0), or antagonistic (FICI>4.0) effect.
[0086] 4. Cytotoxicity to host cells
[0087] Cell viability was measured using the CellTiter-Blue® cell viability assay. The assay was performed according to the manufacturer’s instructions (Promega). Briefly, THP-1 monocyte- derived macrophages were seeded into tissue culture-treated 96-well plates at a density of 5 × 104cells per well and differentiated into macrophages for 72 h in the presence of 40 ng / mL PMA. AAttorney Docket 10457-551PC0 150 μl aliquot of the AgNP stock mixed with 150 μl of RPMI 1640 medium was added to the top row of a new 96-well plate, and 150 μL of culture medium was added to rows B-H, followed by 1:2 serial dilutions from row A through G, leaving H as the untreated control. The medium was aspirated from the wells containing cells, washed twice with phosphate-buffered saline (PBS), followed by a transfer of 100 μl of the diluted AgNPs or plain medium, and incubated for additional 24 h. Following the incubation, the medium was aspirated, cells were washed twice with PBS, and fresh medium and CellTiter-Blue® viability reagent were added at 100 and 20 μl volumes, respectively. The plate was incubated for an additional 24 h. The absorbance was measured via optical density at OD570 and OD600 in the Tecan Infinite 200 Pro microplate reader. The cytotoxicity was determined by subtracting the OD570values (absorption maximum for resorufin) from the OD600(absorption maximum for resazurin reference) values, normalizing the values to the untreated control, and calculating the percent of cells alive. The viability was also tested using HeLa cells, RAW 264.7 macrophages, and mESCs. Each cell line was treated with AgNPs for times specified for each of the experiments. All cell lines were tested with three independent runs. RAW 264.7 and THP1 macrophages were tested with two replicates per run, while HeLa and mESCs were tested with three replicates per run.
[0088] 5. Bacterial uptake by macrophages
[0089] RAW 264.7 macrophages were seeded and incubated overnight as described above in tissue culture-treated 96-well plates at a density of 5 × 104cells / mL. The cells were allowed to attach overnight. AgNPs were serially diluted from stock concentrations as described above. Cells were washed twice with PBS, and AgNPs dilutions were transferred to the 96-well plate containing cells and incubated for 4 h. An overnight culture of E. coli DH5α was adjusted to an OD600 of 1.0 and diluted in DMEM. AgNP-containing medium was aspirated, and cells were washed twice with PBS. Bacteria were added to the cells at a multiplicity of infection (MOI) of 10 and the plates were centrifuged at 2200 RPMs for 30 min at 37°C, followed by a 30-min incubation at 37°C and 5% CO2. After the incubation, the well content was replaced with a fresh medium containing 100 μg / mL gentamicin to eliminate extracellular bacteria. The plates were incubated for 1 h. The medium was then aspirated, cells were washed twice with PBS, and lysed with 100 μl of 0.05% Triton X-100 for 18 min. The lysate was serially diluted at 1:10 and 10 μl from each well was plated on LB agar plates. LB plates were incubated overnight at 37°C, followed by CFUAttorney Docket 10457-551PC0 enumeration. The procedure was repeated with THP-1 cells with a 24-h pre-treatment and PMA differentiation, as described above. Experiments were performed with three independent runs of three replicates per run.
[0090] 6. Measuring eukaryotic translational fidelity
[0091] To measure the stop codon readthrough, a stop codon was inserted between Rluc and Fluc (Fujii et al., 2018). The constructs monitoring translation error were transfected to mESC in 24- well plates using Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen). The transfected cells were treated with aminoglycoside antibiotics (gentamicin and paromomycin) for 6 h post-transfection, followed by an 18 h incubation, while the experimental group was treated with 3.1 μg / mL AgNPs for 18 h. For the combination experiment, AgNPs were mixed in the presence of aminoglycosides (amikacin and gentamicin) at concentrations indicated in the figure legend. Cells were washed with PBS and samples were harvested by Passive Lysis Buffer and assayed using the Dual-Luciferase kit (Promega). To measure the mistranslation rate, the input amount was normalized by measuring the ratio between Fluc / Rluc activity and normalized to a no- treatment control. The translation error rate was expressed as the relative ratio of Fluc to Rluc, which represent the fidelity of protein synthesis.
[0092] 7. Paraformaldehyde killing of Escherichia coli OP50
[0093] Paraformaldehyde (PFA) killing of E. coli OP50 was performed as described previously (Beydoun et al., 2021). Briefly, a 200 μl aliquot from a frozen laboratory glycerol stock of E. coli OP50 was added to 200 mL of LB medium, then incubated for 16 h at 37°C, shaking at 220 rpm. PFA was added to a final concentration of 0.5% v / v and was incubated for 1 hour at 37°C, shaking at 220 rpm. The culture was centrifuged at 3000 RCF for 20 min. The supernatant was removed, bacteria were washed four times with fresh LB medium, and the culture was resuspended in 20 mL of fresh LB medium. The lack of viability was confirmed by plating for CFUs.
[0094] 8. Effect of AgNPs on Caenorhabditis elegans motility
[0095] Motility was assessed by adapting the thrashing assay described elsewhere (Sawin et al., 2000). Worms were age-synchronized to the L1 stage by bleaching (Porta-de-la-Riva et al., 2012). Briefly, worms were grown to the gravid adult stage on NGM plates seeded with E. coli OP50. The worms were washed with M9 minimal medium to remove the bacteria from the surface, thenAttorney Docket 10457-551PC0 incubated with an alkaline hypochlorite solution until the adult tissues began dissolving. The reaction was stopped with M9, and the alkaline hypochlorite solution was washed off with M9 three times. Worms were incubated at room temperature on a nutator in M9 overnight. Synchronized worms were plated onto plain and AgNP-supplemented (0.2 and 1.0 μg / mL) NGM plates seeded with PFA-killed E. coli OP50, followed by a 72-h incubation. Following the incubation, a single worm was placed into a drop of M9 on a microscope slide and allowed to acclimate for 1 min. The rate of motility was recorded as the number of body bends in 30 s. A body bend was defined as an approximately 90° bend along the midline with a decrease in nose-to-tail distance. The experiment was repeated twice with a total of 40 worms per treatment.
[0096] 9. Lifespan of Caenorhabditis elegans
[0097] L1 stage age-synchronized worms were plated onto fresh NGM seeded with live E. coli OP50 and cultured until the young adult stage (~42 h at 25°C). Twenty worms were picked onto NGM plates containing 100 μg / mL of 5′-fluorodeoxyuridine (FUDR), either 0, 0.2, or 1.0 μg / mL AgNPs, and a PFA-killed E. coli OP50 lawn. The experiment was performed using five plates (n = 100) per each condition. Prior to lifespan experiments, the effect of AgNPs and FUDR on E. coli OP50 was assessed using a method described in 2.3.
[0098] 10. Transmission electron microscopy of bacterial cells
[0001] Cells treated with AgNPs were compared with control cells using TEM. E. coli samples were grown overnight, as previously described. Bacterial cells were incubated with water (control group), 0.2, 3.1, or 7.2 μg / mL AgNP for 6 h. Immediately after incubation, formvar–carbon square mesh grids were cleaned via glow discharge in a PELCO easiGlow Discharge Cleaning System. Ten microliters of each bacterial sample were spotted onto its respective grid and incubated at room temperature for 45–60 s. After incubation, each grid was tapped against filter paper to remove excess liquids from the grid surface. One drop of 0.5% uranyl acetate from a 0.22 μm syringe filter was placed on each grid, covered to shelter from light, and incubated for 15–30 s at room temperature. Grids were tapped against filter paper to remove excess liquids after incubation. Prepared EM grids were placed in a secured, ventilated, dark container overnight to allow the substrate to dry. All grids were imaged using the Tecnai FEI G2 Spirit 120 kV TEM.
[0099] 11. Combination of AgNPs with antimicrobialsAttorney Docket 10457-551PC0
[0100] Antibiotics were diluted in LB media and 100 μl of the dilutions were added to row A of a 96-well plate and 50 μl of LB media were added to the rest of the wells. Two-fold serial dilutions were performed from rows A-G, leaving H as the media-only control. The OD600 of an overnight culture of E. coli DH5α was adjusted to 1.0 and diluted at 1:500 in LB media containing 0.4 μg / mL of AgNPs. Aliquots of 50 μL were added to each well, further diluting AgNPs and bacteria to final concentrations of 0.2 μg / mL and 1:1,000, respectively. Bacterial growth was measured via OD600 using the Tecan Infinite Pro 200 for 20 h at 37°C every 30 min with a 5-s orbital shake before each read. Experiments were performed with three independent runs of three replicates per run. According to the European Committee on Antimicrobial Susceptibility Testing, the fractional inhibitory concentration (FIC) index was calculated and described as antagonistic (FIC ≥2), indifferent (1 < FIC <2), additive (0.5 < FIC ≤1), or synergistic (FIC ≤ 0.5; EUCAST, 2000).
[0101] 12. Statistical analysis
[0001] Student’s t-test, one-way analysis of variance (ANOVA), and Kaplan–Meier survival analyzes were used to determine statistical significance. The data were considered statistically significant when p < 0.05. Statistical significance was indicated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Error bars represent the standard error of the mean (SEM). All statistical analyzes were performed using GraphPad Prism version 9.4.0 for Windows (GraphPad Software). Example 2: Characterization of AgNPs
[0102] While various formulations of AgNPs are available for research and public use, most, if not all of them, exhibit some level of antibacterial activity. Commercially available AgNPs were used to investigate their antimicrobial properties and potential utility for future applications that could limit the need for traditional antibiotics. The average Ag concentrations of Formula 1 and Formula 2 measured by AAS were 12.3 ± 0.2 μg / mL and 26.8 ± 0.5 μg / mL, respectively (Table 4). To determine the representative AgNP size distribution, five batches of two different formulations (Formula 1 and 2) were imaged by TEM. Two grids from each batch were imaged, and a minimum of three images from each grid were used, resulting in a robust sample size of over 37,000 and 23,000 particles from Formula 1 and 2, respectively. The resulting mean particle size in Formula 1 was 2.53 ± 1.71 and 3.06 ± 2.04 nm in Formula 2 (Figures 1A,B;B; Figure 10). Size distribution analysis revealed that particles range between 0.8 and 23 nm, with over 99% of particles beingAttorney Docket 10457-551PC0 < 10 nm in diameter (Figure 1B). HAADF-STEM imaging using a Cs probe-corrected FEI Themis S / TEM was used to observe the atomic structure of the AgNPs (Figure 1C). For particles approximately 2 nm and larger, a clear crystalline lattice structure was evident. Additionally, measurement of the spacing of the atomic planes (d spacing) in the AgNPs revealed a commonly observed d spacing of 0.24 ± 0.01 nm. This measured d spacing is basically identical to the largest observable d spacing in elemental Ag of 0.24 nm, corresponding to the {111} family of planes. Thus, the d spacing measurements obtained from HAADF-STEM imaging support that the particles are indeed elemental Ag. For particles smaller than 2 nm, the clear lattice structure was no longer detected (Figure 1C).Atomic absorption spectroscopy was used to measure the Ag concentration of different batches within the two formulations. It was found that the average Ag concentration of Formula 1 was 12.3 μg / mL while Formula 2 was 26.8 μg / mL (Table 4). Example 3: Antimicrobial efficacy
[0103] Next, the antibacterial property of five batches from each formulation was tested. To accomplish this, the MICs of AgNPs were initially measured using E. coli DH5α. Comparable MICs of ~3 μg / mL was found using all samples (Table 4), indicating a consistent antimicrobial property of AgNPs across all five batches from each formulation tested. Because of the similar MICs, only three formulations (Formula 1.1, 2.1, and 2.2) were selected to test the antimicrobial activity against additional bacteria, including P. aeruginosa, A. baumannii, and methicillin- resistant and susceptible S. aureus. Bacterial growth was inhibited in a dose-dependent manner (Figure 2), and all formulations tested were between 2 and 3 times more effective against Gram- negative strains compared with Gram-positive S. aureus strains (Table 5). Among the three samples tested, Formula 1.1 was the most effective against all bacteria, especially the Gram- negative; as such, this formulation was selected for all future experiments. Additionally, Formula 1 was generally more effective than Formula 2, a result that could be attributed to the particle size and which would be in agreement with a known correlation between particle size and antimicrobial efficacy (Morones et al., 2005; Bin Ahmad et al., 2012; Raza et al., 2016; Dong et al., 2019).
[0104] To determine whether AgNPs are also effective against antibiotic-resistant bacteria, isolates from the CDC Antimicrobial Resistance Isolate Bank were used, specifically from the New or Novel Antibiotic Resistance panel. Notably, many bacterial strains within this panel carry mobile colistin resistance (mcr) genes that confer resistance to colistin by modifying the bacterialAttorney Docket 10457-551PC0 cell membrane (Liu et al., 2016; Li et al., 2020). Hyperlinks to the corresponding antibiograms for each strain can be found in Table 3. Given that AgNPs are thought to target the bacterial membrane, these bacteria represent good candidates for antimicrobial tests (Bondarenko et al., 2018). Colistin is also classified as a last-resort polymyxin antibiotic used against Gram-negative aerobic bacteria that are common etiological agents of skin infections (Levin et al., 1999; Garnacho-Montero et al., 2003; Michalopoulos et al., 2005). While the antimicrobial property of AgNPs differed substantially against bacteria with various antibiotic resistance mechanisms, the overall low MIC values that range from 3.1 to 5.5 μg / mL, except for some Salmonella spp., emphasize excellent antibacterial properties against broad antibiotic-resistant bacteria (Figure 2; Table 1). Among the bacteria tested, Salmonella spp. seem to be the least sensitive to AgNPs. Next, the mode of inhibition was assessed. It is generally accepted that if the ratio between the minimum bactericidal concentration (MBC) and the MIC is >4, then the mode of inhibition is bacteriostatic (Pankey and Sabath, 2004). E. coli DH5α was used to determine the MIC by monitoring OD600in the presence of AgNPs over 20 h. The MBC was determined by enumerating the bacteria at the end of the treatment using the CFU plating method. The MIC was 3.125 μg / mL, and the MBC was 6.2 μg / mL, resulting in a ratio of ~2, thus, revealing a bactericidal mode of killing (Figure 3). Example 4: Assessment of AgNP toxicity
[0105] 4.1. Tissue culture: To better understand the effect of AgNPs on various biological systems, in vitro and in vivo models were employed to assess cytotoxicity. The effect of AgNPs on the viability of mouse RAW 264.7 and human THP-1 macrophages, human epithelial HeLa cells, and mouse embryonic stem cells, mESCs was measured. While the epithelial cells were not affected by any of the tested concentrations, the viability of macrophages and mESCs was affected at higher AgNP concentrations; however, no cytotoxicity was detected at lower bactericidal concentrations (<1.6 μg / mL), which already exhibit moderate antibacterial effects at sub-MIC levels (Figures 2, 4A). Previous reports suggest that Ag may target the cell membrane, which in eukaryotic cells could potentially impair the ability of phagocytes to uptake bacteria. To determine the effect of Ag on macrophage-mediated bacterial uptake, the cells were pre-treated for 4 or 24 h with non-toxic AgNP concentrations. It was found that bacterial uptake was not affected at the concentrations tested (Figure 4B).Attorney Docket 10457-551PC0
[0106] 4.2. Proteotoxicity: Previous research suggests that the antibacterial property of Ag is mediated by its ability to target and denature the ribosome (Yamanaka et al., 2005). Similarly, it has been shown that aminoglycoside antibiotics induce misreading of mRNA by bacterial and eukaryotic ribosomes and ultimately lead to translation error which is likely the source of the proteotoxic stress (Krause et al., 2016; Prokhorova et al., 2017; Wohlgemuth et al., 2021). To test whether AgNPs could also induce misreading of mRNA in host cells, translation errors were monitored using reporters that are based on a tandem renilla luciferase (Rluc) and firefly luciferase (Fluc) linked together with a region containing a stop codon. Three different constructs were used, each with a different stop codon (UGA, UAG, or UAA). The stop codon readthrough was monitored by Fluc activity. The mistranslation rate was measured by calculating the ratio between Fluc and Rluc. While a significant increase was seen in mistranslation in the presence of paromomycin and gentamicin, two aminoglycoside antibiotics that kill bacteria by inducing mistranslation (Davis, 1987; Vicens and Westhof, 2001; Kohanski et al., 2008; Krause et al., 2016), no changes was detected in the presence of AgNPs. The stop codon-readthrough was assessed in the presence of E. coli MIC (3.1 μg / mL) concentration of AgNPs. Although this concentration slightly affected the viability of mESCs, any significant effect on translation fidelity was not detected (Figure 4A), indicating that the particles are not proteotoxic to mammalian cells under the tested conditions (Figure 5).
[0107] 4.3. Caenorhabditis elegans: The effects of AgNPs on C. elegans motility and lifespan were measured. The C. elegans model has been routinely used to assess the cytotoxicity of compounds, including AgNPs (Roh et al., 2012; Kim et al., 2017; Luo et al., 2017); as such, this model will allow us to gain further insights into the safety of AgNPs. All tests with C. elegans were performed using control non-treated worms or in the presence of 0.2 and 1.0 μg / mL of AgNPs supplemented into NGM seeded with an E. coli OP50 bacterial lawn as food. 0.2 μg / mL was chosen because this low concentration exhibited a minimal antimicrobial effect in the axenic medium and was non-toxic in tissue culture while 1.0 μg / mL had an intermediate antimicrobial effect (Figure 2). To avoid crowding during lifespan measurements, NGM plates were supplemented with 5-fluoro-2′-deoxyuridine (FUDR). It was found that E. coli OP50 growth is affected by AgNPs and FUDR (Figure 11); therefore, to ensure that bacterial viability will not interfere with the results, motility and lifespan experiments were performed with worms that were fed pre-killed E. coli OP50.Attorney Docket 10457-551PC0
[0108] To evaluate the effect of AgNPs on C. elegans motility, worms were age-synchronized and plated for 72 h on NGM containing AgNPs and dead E. coli OP50 as a food source. A thrashing assay, a commonly used physiological assessment of neuromuscular function (Brignull et al., 2006; Contreras et al., 2014; Zhang et al., 2021) was performed. The assay is performed by counting the number of body bends the worm performs in a 30-s interval when placed in a drop of liquid. The worms on the AgNP-containing plates performed significantly fewer body bends compared with the control (Figure 6A). However, at the same concentrations, AgNPs did not seem to have adverse effects on lifespan as it was found no significant change between the control group and C. elegans cultured on AgNPs (Figure 6B). Example 5: Bacterial morphology
[0109] To determine whether AgNPs induce any visible morphological changes in bacterial cells, TEM was employed to image non-treated E. coli and cells treated with 0.2 μg / mL, 3.1 μg / mL, and 7.2 μg / mL for 6 h. While any obvious morphological changes were not observed in cells incubated with 0.2 and 3.1 μg / mL AgNPs, some changes were observed at 7.2 μg / mL. Interestingly, dark staining of the extracellular matrix seems to increase with AgNP concentration. These dark regions indicate high electron density, suggesting Ag may bind bacterial fimbriae (Figure 7). Moreover, the cells incubated with the highest concentration of AgNPs seem to be darker, which could either indicate an increased Ag concentration or cell permeability which increases uranyl acetate staining. These results warrant further experimentation to confirm fimbriae binding and its possible physiological relevance. Example 6; AgNPs as a potential adjuvant to antimicrobials
[0110] Ag is thought to have multiple cellular targets, including the bacterial membrane, DNA, and ribosome, which are also common antibiotic targets (Dakal et al., 2016). To determine the antimicrobial efficacy of AgNPs in combination with antibiotics having potentially overlapping targets, several antimicrobials with various mechanisms of action that target the membrane, outer membrane, 30S ribosome, 50S ribosome, and dihydrofolate reductase were selected. E. coli DH5α was used to test these antibiotics in combination with 0.2 μg / mL AgNPs, a concentration with a minimal effect (Figure 2). The effect of the combination was assessed by measuring the MIC fold- change as the ratio between the MIC of the antibiotic alone and the MIC of the combination (Table 2; Figure 8A). There was little effect on the MIC when AgNPs were tested in combination withAttorney Docket 10457-551PC0 antimicrobials that target the membrane. The only exception to this was colistin, which had a 6.9- fold decrease in the MIC. Trimethoprim, which targets dihydrofolate reductase (DHFR), had a 2- fold decrease in the MIC (Table 2; Figure 8A). When the AgNPs were combined with ribosome- targeting antibiotics, specifically aminoglycosides, the MICs decreased by up to 22-fold. The strongest synergy between AgNPs and antibiotics was detected with amikacin, an aminoglycoside that targets the 30S ribosome, which resulted in a 22-fold decrease in the MIC. When amikacin and AgNPs were combined at their non-effective concentrations of 0.39 and 0.2 μg / mL, respectively, E. coli DH5α was completely inhibited, indicating a strong synergy between the two (Table 2; Figure 8B). Surprisingly, when the combination with tetracycline was tested, which also targets the 30S ribosomal subunit, any synergistic effect was not observed. Also, any contribution from the potential inhibition by the solvents, DMSO, ethanol, or water at the highest tested dilutions was ruled out (Figure 12). It was thought that perhaps the synergistic effect between AgNPs and aminoglycosides might also affect the host cells by inducing translation errors; however, after testing the combination, no effect on the translation error was found in the host cells (Figure 8C). Further testing of an AgNP dose–response combination with amikacin against MDR E. coli strains using the checkerboard assay also revealed an antimicrobial enhancement (Figure 9). The 0.52 FICI value of the combination treatment used against the MDR, but amikacin- sensitive strain (Figure 9A), indicates a partial synergy. The FICI value for the amikacin-resistant strain could not be calculated. These results further support the AgNP-mediated enhancement of antimicrobial therapies. Collectively, the antimicrobial efficacy of AgNPs and aminoglycosides offers a promising combination treatment strategy for antibiotic-resistant bacteria. TABLE 1 AgNPs have antibacterial activity against clinical isolates with new and emerging resistance genes. Bacteria AR bank number Novel resistance genes MIC (μg / mL) .6 .6 .0 .0Attorney Docket 10457-551PC0 E. coli 0493 mcr-1 3.1 ± 0.0 E li 0494 r-1 31 ± 0.0 .0 .6 .4 .0Attorney Docket 10457-551PC0 TABLE 2 AgNPs synergize with antibiotics against E. coli. Treatment Target MIC (μg / mL) MIC of antibiotic Fold (μg / mL)+AgNPs (0.2μg / mL) change A P 1 .80 .94 .94 .0 .0 .0 .3 .4 .9 .0.2 .9 12 19 22Table 3 Bacterial Strains Strain Source Identifier Escherichia coli OP50 Caenorhabditis Genetics Center WB OP50; RRID:WE-Attorney Docket 10457-551PC0 Fetal Bovine Serum (FBS) Genesee Scientific Cat#25-514 Phosphate Buffer Saline (PBS) Genesee Scientific Cat#25-507B Bacto-Peptone Becton, Dickinson and Company Cat#211677 Fisher BioReagents™ Agar Fisher Scientific Cat#9002-18-0 co twAttorney Docket 10457-551PC0 Table 4 Silver Particle L)Table 5 Minimum Inhibitory Concentrations, μg / mL Formula E. coli P. aeruginosa A. baumannii S. aureus MRSAREFERENCES 1. Ali S., Perveen S., Shah M. R., Zareef M., Arslan M., Basheer S., et al.. (2020). Bactericidal potentials of silver and gold nanoparticles stabilized with cefixime: a strategy against antibiotic-resistant bacteria. J. Nanopart. Res. 22:201. doi: 10.1007 / s11051-020-04939-y 2. Alsaleh N. B., Minarchick V. C., Mendoza R. P., Sharma B., Podila R., Brown J. M. (2019). Silver nanoparticle immunomodulatory potential in absence of direct cytotoxicity in RAW 264.7 macrophages and MPRO 2.1 neutrophils. J. Immunotoxicol. 16, 63–73. doi: 10.1080 / 1547691X.2019.1588928 3. Bayard I. P. E., Grobbelaar A. O., Constantinescu M. A. (2021). Necrotizing fasciitis caused by mono-bacterial gram-negative infection with E. coli - the deadliest of them all: a case series and review of the literature. JPRAS Open 29, 99–105. doi: 10.1016 / j.jpra.2021.04.007, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]Attorney Docket 10457-551PC0 4. Beydoun S., Choi H. S., Dela-Cruz G., Kruempel J., Huang S., Bazopoulou D., et al.. (2021). An alternative food source for metabolism and longevity studies in Caenorhabditis elegans. Commun. Biol. 4:258. doi: 10.1038 / s42003-021-01764-4 5. Bin Ahmad M., Lim J. J., Shameli K., Ibrahim N. A., Tay M. Y., Chieng B. W. (2012). Antibacterial activity of silver bionanocomposites synthesized by chemical reduction route. Chem. Cent. J. 6:101. doi: 10.1186 / 1752-153X-6-101 6. Bondarenko O. M., Sihtmäe M., Kuzmičiova J., Ragelienė L., Kahru A., Daugelavičius R. (2018). Plasma membrane is the target of rapid antibacterial action of silver nanoparticles in Escherichia coli and Pseudomonas aeruginosa. Int. J. Nanomedicine 13, 6779–6790. doi: 10.2147 / ijn.S177163 7. Bose D., Chatterjee S. (2016). Biogenic synthesis of silver nanoparticles using guava (Psidium guajava) leaf extract and its antibacterial activity against Pseudomonas aeruginosa. Appl. Nanosci. 6, 895–901. doi: 10.1007 / s13204-015-0496-5 8. Boucher H. W., Talbot G. H., Bradley J. S., Edwards J. E., Gilbert D., Rice L. B., et al.. (2009). Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin. Infect. Dis. 48, 1–12. doi: 10.1086 / 595011 9. Breijyeh Z., Jubeh B., Karaman R. (2020). Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules 25:1340. doi: 10.3390 / molecules25061340 10. Brenner S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71–94. doi: 10.1093 / genetics / 77.1.71 11. Brignull H. R., Moore F. E., Tang S. J., Morimoto R. I. (2006). Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan- neuronal Caenorhabditis elegans model. J. Neurosci. 26, 7597–7606. doi: 10.1523 / jneurosci.0990-06.2006 12. Brown A. N., Smith K., Samuels T. A., Lu J., Obare S. O., Scott M. E. (2012). Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl. Environ. Microbiol. 78, 2768–2774. doi: 10.1128 / aem.06513-11 13. Bruna T., Maldonado-Bravo F., Jara P., Caro N. (2021). Silver nanoparticles and their antibacterial applications. Int. J. Mol. Sci. 22:7202. doi: 10.3390 / ijms22137202 14. Campo-Beleño C., Villamizar-Gallardo R. A., López-Jácome L. E., González E. E., Muñoz- Carranza S., Franco B., et al.. (2022). Biologically synthesized silver nanoparticles as potent antibacterial effective against multidrug-resistant Pseudomonas aeruginosa. Lett. Appl. Microbiol. 75, 680–688. doi: 10.1111 / lam.13759 15. CDC . (2013). Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention (U.S.). Available at: https: / / www.cdc.gov / drugresistance / pdf / ar- threats-2013-508.pdf (Accessed July 1, 2022).Attorney Docket 10457-551PC0 16. CDC . (2019). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.). Available at: https: / / stacks.cdc.gov / view / cdc / 82532 (Accessed July 1, 2022). 17. Chinnasamy G., Chandrasekharan S., Koh T. W., Bhatnagar S. (2021). Synthesis, characterization, antibacterial and wound healing efficacy of silver nanoparticles from Azadirachta indica. Front. Microbiol. 12:611560. doi: 10.3389 / fmicb.2021.611560 18. Contreras E. Q., Puppala H. L., Escalera G., Zhong W., Colvin V. L. (2014). Size-dependent impacts of silver nanoparticles on the lifespan, fertility, growth, and locomotion of Caenorhabditis elegans. Environ. Toxicol. Chem. 33, 2716–2723. doi: 10.1002 / etc.2705 19. Dakal T. C., Kumar A., Majumdar R., Yadav V. (2016). Mechanistic basis of antimicrobial actions of silver nanoparticles. Front. Microbiol. 7:1831. doi: 10.3389 / fmicb.2016.01831 20. Davis B. D. (1987). Mechanism of bactericidal action of aminoglycosides. Microbiol. Rev. 51, 341–350. doi: 10.1128 / mr.51.3.341-350.1987 21. Desouky E. M., Shalaby M. A., Gohar M. K., Gerges M. A. (2020). Evaluation of antibacterial activity of silver nanoparticles against multidrug-resistant gram negative bacilli clinical isolates from Zagazig University hospitals. Microbes Infect. Dis. 1, 15–23. doi: 10.21608 / mid.2020.27148.1003 22. Dong Y., Zhu H., Shen Y., Zhang W., Zhang L. (2019). Antibacterial activity of silver nanoparticles of different particle size against Vibrio natriegens. PLoS One 14:e0222322. doi: 10.1371 / journal.pone.0222322 23. El-Aassar M. R., Ibrahim O. M., Fouda M. M. G., Fakhry H., Ajarem J., Maodaa S. N., et al.. (2021). Wound dressing of chitosan-based-crosslinked gelatin / polyvinyl pyrrolidone embedded silver nanoparticles, for targeting multidrug resistance microbes. Carbohydr. Polym. 255:117484. doi: 10.1016 / j.carbpol.2020.117484 24. El-Sayed Ahmed M. A. E., Zhong L. L., Shen C., Yang Y., Doi Y., Tian G. B. (2020). Colistin and its role in the era of antibiotic resistance: an extended review (2000- 2019). Emerg. Microbes Infect. 9, 868–885. doi: 10.1080 / 22221751.2020.1754133, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar] 25. EUCAST (2000). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin. Microbiol. Infect. 6, 503–508. doi: 10.1046 / j.1469- 0691.2000.00149.x 26. Falagas M. E., Kasiakou S. K. (2005). Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333–1341. doi: 10.1086 / 429323 27. Franci G., Falanga A., Galdiero S., Palomba L., Rai M., Morelli G., et al.. (2015). Silver nanoparticles as potential antibacterial agents. Molecules 20, 8856–8874. doi: 10.3390 / molecules20058856Attorney Docket 10457-551PC0 28. Fujii K., Susanto T. T., Saurabh S., Barna M. (2018). Decoding the function of expansion segments in ribosomes. Mol. Cell 72, 1013–1020.e6. doi: 10.1016 / j.molcel.2018.11.023 29. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F. J., Barrero-Almodóvar A. E., García-Garmendia J. L., Bernabeu-Wittell M., et al.. (2003). Treatment of multidrug- resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous Colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36, 1111–1118. doi: 10.1086 / 374337 30. Haase A., Mantion A., Graf P., Plendl J., Thuenemann A. F., Meier W., et al.. (2012). A novel type of silver nanoparticles and their advantages in toxicity testing in cell culture systems. Arch. Toxicol. 86, 1089–1098. doi: 10.1007 / s00204-012-0836-0 31. Hobbie S. N., Akshay S., Kalapala S. K., Bruell C. M., Shcherbakov D., Böttger E. C. (2008). Genetic analysis of interactions with eukaryotic rRNA identify the Mitoribosome as target in aminoglycoside ototoxicity. Proc. Natl. Acad. Sci. U. S. A. 105, 20888–20893. doi: 10.1073 / pnas.0811258106 32. Hong S., Harris K. A., Fanning K. D., Sarachan K. L., Frohlich K. M., Agris P. F. (2015). Evidence that antibiotics bind to human mitochondrial ribosomal RNA has implications for aminoglycoside toxicity. J. Biol. Chem. 290, 19273–19286. doi: 10.1074 / jbc.M115.655092 33. Jung W. K., Koo H. C., Kim K. W., Shin S., Kim S. H., Park Y. H. (2008). Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl. Environ. Microbiol. 74, 2171–2178. doi: 10.1128 / aem.02001-07 34. Kakasis A., Panitsa G. (2019). Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int. J. Antimicrob. Agents 53, 16–21. doi: 10.1016 / j.ijantimicag.2018.09.004 35. Kim J. S., Kuk E., Yu K., Kim J.-H., Park S. J., Lee H.-J., et al.. (2007). Antimicrobial effects of silver nanoparticles. Nanomedicine 3, 95–101. doi: 10.1016 / J.NANO.2006.12.001 36. Kim J. H., Lee S. H., Cha Y. J., Hong S. J., Chung S. K., Park T. H., et al.. (2017). C. elegans- on-a-chip for in situ and in vivo Ag nanoparticles’ uptake and toxicity assay. Sci. Rep. 7:40225. doi: 10.1038 / srep40225 37. Kohanski M. A., Dwyer D. J., Wierzbowski J., Cottarel G., Collins J. J. (2008). Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cells 135, 679–690. doi: 10.1016 / j.cell.2008.09.038, 38. Krause K. M., Serio A. W., Kane T. R., Connolly L. E. (2016). Aminoglycosides: an overview. Cold Spring Harb. Perspect. Med. 6:a027029. doi: 10.1101 / cshperspect.a027029, 39. Lara H. H., Ayala-Núnez N. V., Ixtepan Turrent L. D. C., Rodríguez Padilla C. (2010). Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J. Microbiol. Biotechnol. 26, 615–621. doi: 10.1007 / s11274-009-0211-3Attorney Docket 10457-551PC0 40. Levin A. S., Barone A. A., Penço J., Santos M. V., Marinho I. S., Arruda E. A., et al.. (1999). Intravenous colistin as therapy for nosocomial infections caused by multidrug- resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28, 1008–1011. doi: 10.1086 / 514732 41. Li W.-R., Sun T.-L., Zhou S.-L., Ma Y.-K., Shi Q.-S., Xie X.-B., et al.. (2017). A comparative analysis of antibacterial activity, dynamics, and effects of silver ions and silver nanoparticles against four bacterial strains. Int. Biodeterior. Biodegradation 123, 304–310. doi: 10.1016 / j.ibiod.2017.07.015 42. Li B., Yin F., Zhao X., Guo Y., Wang W., Wang P., et al.. (2020). Colistin resistance gene mcr-1 mediates cell permeability and resistance to hydrophobic antibiotics. Front. Microbiol. 10:3015. doi: 10.3389 / fmicb.2019.03015 43. Liao S., Zhang Y., Pan X., Zhu F., Jiang C., Liu Q., et al.. (2019). Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa. Int. J. Nanomed. 14, 1469–1487. doi: 10.2147 / ijn.S191340 44. Liu Y.-Y., Wang Y., Walsh T. R., Yi L.-X., Zhang R., Spencer J., et al.. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161–168. doi: 10.1016 / S1473-3099(15)00424-7 45. Luo X., Xu S., Yang Y., Li L., Chen S., Xu A., et al.. (2016). Insights into the ecotoxicity of silver nanoparticles transferred from Escherichia coli to Caenorhabditis elegans. Sci. Rep. 6:36465. doi: 10.1038 / srep36465 46. Luo X., Xu S., Yang Y., Zhang Y., Wang S., Chen S., et al.. (2017). A novel method for assessing the toxicity of silver nanoparticles in Caenorhabditis elegans. Chemosphere 168, 648–657. doi: 10.1016 / j.chemosphere.2016.11.011 47. Malawong S., Thammawithan S., Sirithongsuk P., Daduang S., Klaynongsruang S., Wong P. T., et al.. (2021). Silver nanoparticles enhance antimicrobial efficacy of antibiotics and restore that efficacy against the melioidosis pathogen. Antibiotics (Basel) 10:839. doi: 10.3390 / antibiotics10070839 48. Michalopoulos A. S., Tsiodras S., Rellos K., Mentzelopoulos S., Falagas M. E. (2005). Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11, 115– 121. doi: 10.1111 / j.1469-0691.2004.01043.x 49. Miró-Canturri A., Ayerbe-Algaba R., Smani Y. (2019). Drug repurposing for the treatment of bacterial and fungal infections. Front. Microbiol. 10:41. doi: 10.3389 / fmicb.2019.00041 50. Moffarah A. S., Al Mohajer M., Hurwitz B. L., Armstrong D. G. (2016). Skin and soft tissue infections. Microbiol. Spectr. 4:14. doi: 10.1128 / microbiolspec.DMIH2-0014-2015 51. Mohamed M. S. M., Mostafa H. M., Mohamed S. H., Abd El-Moez S. I., Kamel Z. (2020). Combination of silver nanoparticles and vancomycin to overcome antibioticAttorney Docket 10457-551PC0 resistance in planktonic / biofilm cell from clinical and animal source. Microb. Drug Resist. 26, 1410–1420. doi: 10.1089 / mdr.2020.0089 52. Mohanta Y. K., Biswas K., Jena S. K., Hashem A., Abd Allah E. F., Mohanta T. K. (2020). Anti-biofilm and antibacterial activities of silver nanoparticles synthesized by the reducing activity of phytoconstituents present in the Indian medicinal plants. Front. Microbiol. 11:1784. doi: 10.3389 / fmicb.2020.01784 53. Morones J., Elechiguerra J. L., Camacho A., Holt K., Kourí J., Ramirez J. T., et al.. (2005). The bactericidal effect of silver nanoparticles. Nanotechnology 16, 2346–2353. doi: 10.1088 / 0957-4484 / 16 / 10 / 059 54. Moyer C., Brentano L., Gravens D. L., Margraf H. W., Monafo W. W. (1965). Treatment of large human burns with 0.5 per cent AgNO3 solution. Arch. Surg. 90, 812–867. doi: 10.1001 / archsurg.1965.01320120014002 55. Murray C. J. L., Ikuta K. S., Sharara F., Swetschinski L., Robles Aguilar G., Gray A., et al.. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655. doi: 10.1016 / S0140-6736(21)02724-0 56. Musino D., Devcic J., Lelong C., Luche S., Rivard C., Dalzon B., et al.. (2021). Impact of Physico-chemical properties of cellulose nanocrystal / silver nanoparticle hybrid suspensions on their biocidal and toxicological effects. Nano 11:1862. doi: 10.3390 / nano11071862 57. Naqvi S. Z. H., Kiran U., Ali M. I., Jamal A., Hameed A., Ahmed S., et al.. (2013). Combined efficacy of biologically synthesized silver nanoparticles and different antibiotics against multidrug-resistant bacteria. Int. J. Nanomedicine 8, 3187–3195. doi: 10.2147 / IJN.S49284 58. Pal S., Tak Y., Song J. (2007). Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol. 73, 1712–1720. doi: 10.1128 / aem.02218-06 59. Panáček A., Smékalová M., Večeřová R., Bogdanová K., Röderová M., Kolář M., et al.. (2016). Silver nanoparticles strongly enhance and restore bactericidal activity of inactive antibiotics against multiresistant Enterobacteriaceae. Colloids Surf. B: Biointerfaces 142, 392–399. doi: 10.1016 / j.colsurfb.2016.03.007 60. Pankey G. A., Sabath L. D. (2004). Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38, 864–870. doi: 10.1086 / 381972 61. Park H.-J., Kim J. Y., Kim J., Lee J.-H., Hahn J.-S., Gu M. B., et al.. (2009). Silver-ion- mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 43, 1027–1032. doi: 10.1016 / j.watres.2008.12.002 62. Porta-de-la-Riva M., Fontrodona L., Villanueva A., Cerón J. (2012). Basic Caenorhabditis elegans methods: synchronization and observation. J. Vis. Exp. 64:4019. doi: 10.3791 / 4019Attorney Docket 10457-551PC0 63. Prokhorova I., Altman R. B., Djumagulov M., Shrestha J. P., Urzhumtsev A., Ferguson A., et al.. (2017). Aminoglycoside interactions and impacts on the eukaryotic ribosome. Proc. Natl. Acad. Sci. 114, E10899–E10908. doi: 10.1073 / pnas.1715501114 64. Radzig M. A., Nadtochenko V. A., Koksharova O. A., Kiwi J., Lipasova V. A., Khmel I. A. (2013). Antibacterial effects of silver nanoparticles on gram-negative bacteria: influence on the growth and biofilms formation, mechanisms of action. Colloids Surf. B: Biointerfaces 102, 300–306. doi: 10.1016 / j.colsurfb.2012.07.039 65. Rai M., Yadav A., Gade A. (2009). Silver nanoparticles as a new generation of antimicrobials. Biotechnol. Adv. 27, 76–83. doi: 10.1016 / j.biotechadv.2008.09.002 66. Raza M. A., Kanwal Z., Rauf A., Sabri A. N., Riaz S., Naseem S. (2016). Size- and shape- dependent antibacterial studies of silver nanoparticles synthesized by wet chemical routes. Nanomaterials (Basel) 6:74. doi: 10.3390 / nano6040074 67. Roh J.-Y., Eom H.-J., Choi J. (2012). Involvement of Caenohabditis elegans MAPK signaling pathways in oxidative stress response induced by silver nanoparticles exposure. Toxicol. Res. 28, 19–24. doi: 10.5487 / TR.2012.28.1.019 68. Sarowska J., Futoma-Koloch B., Jama-Kmiecik A., Frej-Madrzak M., Ksiazczyk M., Bugla- Ploskonska G., et al.. (2019). Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports. Gut Pathog. 11:10. doi: 10.1186 / s13099-019-0290-0 69. Sawin E. R., Ranganathan R., Horvitz H. R. (2000). C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26, 619–631. doi: 10.1016 / S0896-6273(00)81199-X, PMID: 70. Sebeny P. J., Riddle M. S., Petersen K. (2008). Acinetobacter baumannii skin and soft-tissue infection associated with war trauma. Clin. Infect. Dis. 47, 444–449. doi: 10.1086 / 590568 71. Shahverdi A. R., Fakhimi A., Shahverdi H. R., Minaian S. (2007). Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 3, 168–171. doi: 10.1016 / j.nano.2007.02.001 72. Shrivastava S., Bera T., Roy A., Singh G., Ramachandrarao P., Dash D. (2007). Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 18:225103. doi: 10.1088 / 0957-4484 / 18 / 22 / 225103 73. Siddique M. H., Aslam B., Imran M., Ashraf A., Nadeem H., Hayat S., et al.. (2020). Effect of silver nanoparticles on biofilm formation and EPS production of multidrug- resistant Klebsiella pneumoniae. Biomed. Res. Int. 2020:6398165. doi: 10.1155 / 2020 / 6398165 74. Sim W., Barnard R. T., Blaskovich M. A. T., Ziora Z. M. (2018). Antimicrobial silver in medicinal and consumer applications: a patent review of the past decade (2007– 2017). Antibiotics 7:93. doi: 10.3390 / antibiotics7040093Attorney Docket 10457-551PC0 75. Spurbeck R. R., Stapleton A. E., Johnson J. R., Walk S. T., Hooton T. M., Mobley H. L. T. (2011). Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of Ygi and Yad fimbriae. Infect. Immun. 79, 4753–4763. doi: 10.1128 / IAI.05621-11 76. Thammawithan S., Srichaiyapol O., Siritongsuk P., Daduang S., Klaynongsruang S., Prapasarakul N., et al.. (2021). Anisotropic silver nanoparticles gel exhibits antibacterial action and reduced scar formation on wounds contaminated with methicillin- resistant Staphylococcus pseudintermedius (MRSP) in a mice model. Animals 11:3412. doi: 10.3390 / ani11123412 77. Vicens Q., Westhof E. (2001). Crystal structure of paromomycin docked into the eubacterial ribosomal decoding a site. Structure 9, 647–658. doi: 10.1016 / S0969-2126(01)00629-3 78. Wohlgemuth I., Garofalo R., Samatova E., Günenç A. N., Lenz C., Urlaub H., et al.. (2021). Translation error clusters induced by aminoglycoside antibiotics. Nat. Commun. 12:1830. doi: 10.1038 / s41467-021-21942-6 79. Wu D. C., Chan W. W., Metelitsa A. I., Fiorillo L., Lin A. N. (2011). Pseudomonas skin infection. Am. J. Clin. Dermatol. 12, 157–169. doi: 10.2165 / 11539770-000000000-00000 80. Yamanaka M., Hara K., Kudo J. (2005). Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis. Appl. Environ. Microbiol. 71, 7589–7593. doi: 10.1128 / AEM.71.11.7589-7593.2005 81. Zhang W., Li W., Li J., Chang X., Niu S., Wu T., et al.. (2021). Neurobehavior and neuron damage following prolonged exposure of silver nanoparticles with / without polyvinylpyrrolidone coating in Caenorhabditis elegans. J. Appl. Toxicol. 41, 2055–2067. doi: 10.1002 / jat.4197 82. Zhou L., Zhao X., Li M., Yan L., Lu Y., Jiang C., et al.. (2021). Antibacterial and wound healing–promoting effect of sponge-like chitosan-loaded silver nanoparticles biosynthesized by iturin. Int. J. Biol. Macromol. 181, 1183–1195. doi: 10.1016 / j.ijbiomac.2021.04.119 83. Jeong Y, Lim DW, Choi J. Assessment of size-dependent antimicrobial and cytotoxic properties of silver nanoparticles. Adv Mater Sci Eng. 2014. 763807, 84. Wu M, Guo H, Liu L, Liu Y, Xie L. Size-dependent cellular uptake and localization profiles of silver nanoparticles. Int J Nanomedicine. 2019;14:4247–4259. 85. El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM. Surface charge-dependent toxicity of silver nanoparticles. Environ sci technol. 2010;45:283–287 86. Ju-Nam Y, Lead JR. Manufactured nanoparticles: An overview of their chemistry, interactions and potential environmental implications. Sci Total Environ.2008;400:396–414. 87. Yadav TP, Yadav RM, Singh DP. Mechanical milling: a top down approach for the synthesis of nanomaterials and nanocomposites. Nanosci Nanotechnol. 2012;2:22–48.Attorney Docket 10457-551PC0 88. Vreeland EC, Watt J, Schober GB, Hance BG, Austin MJ, Price AD. et al. Enhanced nanoparticle size control by extending LaMer's mechanism. Chem Mater. 2015;27:6059– 6066. 89. Naik AN, Patra S, Sen D, Goswami A. Evaluating the mechanism of nucleation and growth of silver nanoparticles in a polymer membrane under continuous precursor supply: tuning of multiple to single nucleation pathway. Phys Chem Chem Phys. 2019;21:4193–4199. 90. Elsupikhe RF, Shameli K, Ahmad MB. Sonochemical method for the synthesis of silver nanoparticles in κ-carrageenan from silver salt at different concentrations. Res Chem Intermediat. 2015;41:8515–8525. 91. Pu F, Ran X, Guan M, Huang Y, Ren J, Qu X. Biomolecule-templated photochemical synthesis of silver nanoparticles: Multiple readouts of localized surface plasmon resonance for pattern recognition. Nano Res. 2018;11:3213–3221. 92. Joseph S, Mathew B. Microwave-assisted green synthesis of silver nanoparticles and the study on catalytic activity in the degradation of dyes. J Mol Liq. 2015;204:184–191. 93. Pompilio A, Geminiani C, Bosco D, Rana R, Aceto A, Bucciarelli T. et al. Electrochemically Synthesized Silver Nanoparticles Are Active Against Planktonic and Biofilm Cells of Pseudomonas aeruginosa and Other Cystic Fibrosis-Associated Bacterial Pathogens. Front Microbiol. 2018;9:1349. 94. Pantidos N. Biological Synthesis of Metallic Nanoparticles by Bacteria, Fungi and Plants. J Nanomed Nanotechnol. 2014;5:233. 95. de Morais MG, Vaz BdS, de Morais EG, Costa JAV. Biologically active metabolites synthesized by microalgae. Biomed Res Int. 2015. 435265. 96. Hamedi S, Ghaseminezhad M, Shokrollahzadeh S, Shojaosadati SA. Controlled biosynthesis of silver nanoparticles using nitrate reductase enzyme induction of filamentous fungus and their antibacterial evaluation. Artif Cells Nanomed Biotechnol. 2017;45:1588–1596. 97. Al Abboud MA. Fungal biosynthesis of silver nanoparticles and their role in control of fusarium wilt of sweet pepper and soil-borne fungi in vitro. Int J Pharmacol. 2018;14:773– 780. 98. Khan MA, Khan T, Nadhman A. Applications of plant terpenoids in the synthesis of colloidal silver nanoparticles. Adv Colloid Interface Sci. 2016;234:132–141. 99. Kuppusamy P, Yusoff MM, Maniam GP, Govindan N. Biosynthesis of metallic nanoparticles using plant derivatives and their new avenues in pharmacological applications- An updated report. Saudi Pharm J. 2016;24:473–484. 100. Xu L, Wang YY, Huang J, Chen CY, Wang ZX, Xie H. Silver nanoparticles: Synthesis, medical applications and biosafety. Theranostics. 2020 Jul 11;10(20):8996-9031.
Claims
Attorney Docket 10457-551PC0 CLAIMS What is claimed is:
1. A method of treating bacterial wound infection in a mammalian subject in need thereof comprising a step of co-administering effective amounts of silver nanoparticles (AgNPs) and antibiotics.
2. The method of claim 1, wherein the antibiotic is selected from the group of aminoglycosides comprising streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate.
3. The method of claim 1 or 2, wherein the antibiotic is gentamicin, tobramycin, amikacin or colistin, and wherein the concentration of the antibiotic is not greater than its minimal inhibitory concentration (MIC).
4. The method of any one of the preceding claims, wherein the dosage form of gentamicin, tobramycin, amikacin or colistin is an injection solution or a topical dosage form selected from solid form of powder or granules, semisolid form of cream, ointment, gel, or paste, liquid form of lotion or liniments, or liposome spray.
5. The method of any one of the preceding claims, wherein the antibiotic is administered through IV or IM route or topical or transdermal route.
6. The method of claim 1, wherein AgNPs are the particles of size range between 0.8 nm and 23 nm, in particular between 2 nm and 10 nm, wherein the mean particle size is 0.5 to 5.0 nm, and wherein the concentration of AgNPs is less than about 0.7µg / ml, less than about 0.6 µg / ml, less than about 0.5 µg / ml, less than about 0.4 µg / ml, less than about 0.3 µg / ml, or less than about 0.2 μg / ml.
7. The method of claim 1 or 6, wherein AgNPs is a topical dosage form selected from solid form of powder or granules, semisolid form of cream, ointment, gel, or paste, liquid form of lotion or liniments, or liposome spray.
8. The method of claim 1, 6 or 7, wherein AgNPs are applied to the wound using a transdermal patch coated with AgNPs or a wound dressing impregnated with AgNPs, wherein the wound dressing materials are selected from gauze, lint, plasters, bandages (natural or synthetic) and cotton wool.Attorney Docket 10457-551PC0 9. The method of claims 4 and 7, wherein the topical dosage form of the antibiotic comprises AgNPs as an adjuvant.
10. The method of claim 1, wherein the targeted bacteria are Gram-negative bacteria as well as multidrug resistant Gram-positive bacteria and Mycobacteria.
11. The method of claim 1 or 10, wherein the targeted bacteria comprise Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Citrobacter freundii as well as multidrug resistant Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium avium complex and M. tuberculosis.
12. A method of treating respiratory diseases caused by bacterial infection in a mammalian subject in need thereof, comprising a step of co-administering effective amounts of silver nanoparticles (AgNPs) and antibiotics.
13. The method of claim 12, wherein the respiratory disease is selected from pneumonia, cystic fibrosis, and multidrug resistant tuberculosis.
14. The method of claim 12, wherein the antibiotic is selected from the group of aminoglycosides comprising streptomycin, kanamycin, amikacin, tobramycin, gentamicin, and netilmicin, or the group of polymyxins comprising polymyxin B, polymyxin E (colistin), and colistimethate.
15. The method of claim 12 or 14, wherein the antibiotic is gentamicin, tobramycin, amikacin or colistin, and wherein the concentration of the antibiotic is not greater than its minimal inhibitory concentration (MIC).
16. The method of claim 12, 14 or 15, wherein the dosage form of gentamicin, tobramycin, amikacin or colistin is an injection solution or a liposome spray for nebulization.
17. The method of any one of claims 12 and 14 to 16, wherein the antibiotic is administered through IV or IM route or nasal route.
18. The method of claim 12, wherein AgNPs are the particles of size range between 0.8 nm and 23 nm, in particular between 2 nm and 10 nm, wherein the mean particle size is 0.5 to 5.0 nm, and wherein the concentration of AgNPs is less than about 0.7µg / ml, less than about 0.6 µg / ml, less than about 0.5 µg / ml, less than about 0.4 µg / ml, less than about 0.3 µg / ml, or less than about 0.2 μg / ml.
19. The method of claim 12 or 18, wherein the dosage form of AgNPs is a liposome spray for nebulization, wherein it is administered through nasal route.Attorney Docket 10457-551PC0 20. The method of claims 17 and 19, wherein the liposome spray for nebulization of the antibiotic comprises the liposome containing AgNPs as an adjuvant.
21. The method of claim 12, wherein the targeted bacteria are Gram-negative bacteria as well as multidrug resistant Gram-positive bacteria and Mycobacteria.
22. The method of claim 12 or 21, wherein the targeted bacteria comprise Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Citrobacter freundii as well as multidrug resistant Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium avium complex and M. tuberculosis.
